Lycopene, a natural pigment with potent antioxidant activity and significant health benefits, is difficult to obtain through conventional approaches because of limited natural sources and the high cost of extraction. Consequently, microbial cell factories have emerged as a promising platform for efficient lycopene production. To achieve high-level lycopene production in Yarrowia lipolytica, an initial biosynthetic pathway was constructed by coexpressing the CrtB and CrtI genes. To enhance precursor supply, a RIAD/RIDD-mediated modular assembly strategy was employed to co-localize IDI and GGS1. Metabolic flux was further enhanced through multi-copy integration of CrtB and CrtI, heterologous expression of the mevalonate pathway enzymes MvaE and MvaSMT, and coordinated expression of ERG12 and GGPPxd. Analysis of downstream catalytic limitations revealed that increasing CrtI expression had a greater effect on lycopene production than increasing CrtB expression. Subsequently, introduction of the mutant enzyme CarRPE78K+Y27R, which relieves substrate inhibition while retaining phytoene synthase activity, significantly increased lycopene accumulation. The final engineered strain, lyc7-6, incorporating these optimization strategies, achieved a lycopene titer of 288.91 mg.L-1. Collectively, systematic engineering of the lycopene biosynthetic pathway through heterologous gene introduction, modular enzyme assembly, multi-copy gene integration, enhancement of precursor supply, and optimization of downstream catalytic efficiency substantially increased lycopene production in Y. lipolytica. These findings provide a framework for the rational design of microbial cell factories for the production of high-value terpenoids.